

YOUR INVITATION TO OUR BREAKFAST SYMPOSIUM

Proudly sponsored by Novo Nordisk®

Wegovy® (semaglutide): A new standard of care in MASH management

National and international guidelines recognise the growing burden of metabolic dysfunction-associated steatohepatitis (MASH), highlighting the need to proactively screen and optimise cardiometabolic management in these patients.¹⁻⁴ The therapeutic landscape is evolving, with Wegovy® (semaglutide) 2.4 mg becoming the first ever indicated medication for adults living with non-cirrhotic moderate to advanced MASH (consistent with F2/F3) in Australia (*provisional approval*), based on the Phase 3 ESSENCE trial.^{5,6*}

Join this multidisciplinary session to hear the evidence behind the indication⁶ and discuss practical approaches to identify eligible patients and implement guideline recommended care.^{3,4} Learn how to integrate Wegovy® into contemporary MASH management and help optimise cardio-metabolic health outcomes in your patients.



Join us for breakfast and an informative discussion on **Sunday August 30th 2026**.
Scan the QR code to register.

AGW 2026

WHEN

Sunday August 30th 2026

Breakfast begins at 7:00 AM

Presentation from 7:20 AM to 8:20 AM

WHERE

**Meeting Room 6;
Perth Exhibition and
Convention Centre**

21 Mounts Bay Rd, Perth WA 6000

SPEAKERS

A/Prof. Marie Sinclair

Gastroenterologist and
Hepatologist, Victorian
Liver Transplant Unit,
Austin Health / Clinical
Associate Professor, The
University of Melbourne,
VIC



Dr Nick Lan

Cardiologist, Fiona
Stanley Hospital /
Clinical Senior Lecturer,
University of Western
Australia, WA



*This indication was approved via the **provisional approval** pathway based on resolution of steatohepatitis and improvement in liver fibrosis. Continued approval of this indication depends on verification and description of clinical benefit in confirmatory trials.⁵ Refer to the Wegovy® Product Information for further details on approved indications.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PBS Information: This product is not listed on the PBS.

Please review full Product Information before prescribing, available at
<https://rss.medsinfo.com.au/no/pi.cfm?product=nopwegov>



Scan QR code to see full
Wegovy® Product Information

MASH: metabolic dysfunction-associated steatohepatitis.

References: 1. Adams LA, *et al. Med J Aust* 2025;223(5):268–276. 2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) *et al. J Hepatol* 2024;81(3):492–542. 3. Bansal MB, *et al. Hepatology*. 2025; DOI:10.1097/HEP.0000000000001608. 4. Younossi ZM, *et al. Clin Gastroenterol Hepatol*. 2026;S1542-3565(26)00241-7. 5. Wegovy® (semaglutide) Approved Product Information. Available at: <https://rss.medsinfo.com.au/no/pi.cfm?product=nopwegov>. 6. Sanyal AJ, *et al. N Engl J Med*. 2025;392(21):2089–2099 (Including supplement).

ONCE-WEEKLY

wegovy®
semaglutide injection

Novo Nordisk Pharmaceuticals Pty Ltd. Level 10, 118 Mount Street, North Sydney NSW 2060. ABN 40 002 879 996. Novo Nordisk® Medical Information (Australia) 1800 668 626. www.novonordisk.com.au.

®Registered trademark of Novo Nordisk A/S. NOV00150. AU26SEMO00331. Date of preparation: August 2026.

